We are seeing increasing desire to see real-world evidence on outcomes and costs for narrower or rarer patient populations, says Amy O'Sullivan, Ontada's SVP and Chief Research Officer. However, small patient populations and sample sizes can make this process challenging. Ontada has been doing a lot of this work, and we look forward to continuing to do so in 2024 and beyond. Watch the full interview.
